Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ADMA NASDAQ:ALLO NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$22.13-0.2%$21.88$16.97▼$28.35$3.79B0.861.71 million shs577,395 shsADMAADMA Biologics$8.49-0.1%$11.52$7.21▼$22.37$2.02B0.835.55 million shs1.37 million shsALLOAllogene Therapeutics$2.23-4.5%$2.39$0.94▼$4.46$547.17M0.468.36 million shs5.56 million shsPCVXVaxcyte$53.68-1.1%$57.78$29.00▼$65.00$7.75B1.31.39 million shs474,686 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+2.12%+3.26%+3.36%+2.64%+28.95%ADMAADMA Biologics+1.07%-15.67%-18.11%-45.48%-57.24%ALLOAllogene Therapeutics+1.30%+0.87%-23.33%+43.83%+106.19%PCVXVaxcyte+0.41%-4.99%-12.15%-1.27%+80.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$22.13-0.2%$21.88$16.97▼$28.35$3.79B0.861.71 million shs577,395 shsADMAADMA Biologics$8.49-0.1%$11.52$7.21▼$22.37$2.02B0.835.55 million shs1.37 million shsALLOAllogene Therapeutics$2.23-4.5%$2.39$0.94▼$4.46$547.17M0.468.36 million shs5.56 million shsPCVXVaxcyte$53.68-1.1%$57.78$29.00▼$65.00$7.75B1.31.39 million shs474,686 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+2.12%+3.26%+3.36%+2.64%+28.95%ADMAADMA Biologics+1.07%-15.67%-18.11%-45.48%-57.24%ALLOAllogene Therapeutics+1.30%+0.87%-23.33%+43.83%+106.19%PCVXVaxcyte+0.41%-4.99%-12.15%-1.27%+80.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.75Moderate Buy$31.0040.08% UpsideADMAADMA Biologics 2.40Hold$19.00123.69% UpsideALLOAllogene Therapeutics 2.69Moderate Buy$8.07262.70% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0060.22% UpsideCurrent Analyst Ratings BreakdownLatest ADMA, ACAD, ALLO, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ACADACADIA Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$33.00 ➝ $32.005/7/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.005/7/2026ADMAADMA Biologics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$24.00 ➝ $20.005/1/2026ACADACADIA Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/1/2026ALLOAllogene Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/27/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/20/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.004/20/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/16/2026ALLOAllogene Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral4/14/2026ALLOAllogene Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$1.60 ➝ $3.854/14/2026ALLOAllogene Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $12.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$1.10B3.46$0.90 per share24.48$7.29 per share3.04ADMAADMA Biologics$509.86M3.97$0.66 per share12.86$1.64 per share5.18ALLOAllogene Therapeutics$20K27,236.23N/AN/A$1.30 per share1.71PCVXVaxcyteN/AN/AN/AN/A$20.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$391M$2.2010.0626.9925.5734.30%9.61%7.07%N/AADMAADMA Biologics$146.93M$0.6812.498.09N/A32.43%39.98%28.08%N/AALLOAllogene Therapeutics-$190.89M-$0.87N/AN/AN/AN/A-57.07%-41.63%N/APCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%N/ALatest ADMA, ACAD, ALLO, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/6/2026Q1 2026ACADACADIA Pharmaceuticals$0.04$0.02-$0.02$0.02$280.25 million$268.10 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A3/12/2026Q4 2025ALLOAllogene Therapeutics-$0.25-$0.17+$0.08-$0.17$0.00 millionN/A2/26/2026Q4 2025ACADACADIA Pharmaceuticals$0.12$1.60+$1.48$1.60$292.54 million$298.00 million2/25/2026Q4 2025ADMAADMA Biologics$0.20$0.20N/A$0.20$139.80 million$139.16 million2/24/2026Q4 2025PCVXVaxcyte-$1.46-$1.80-$0.34-$1.80$18.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AADMAADMA BiologicsN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A3.593.48ADMAADMA Biologics0.516.953.93ALLOAllogene TherapeuticsN/A7.937.93PCVXVaxcyteN/A7.497.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ADMAADMA Biologics75.68%ALLOAllogene Therapeutics83.63%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.20%ADMAADMA Biologics3.90%ALLOAllogene Therapeutics13.20%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510171.24 million126.37 millionOptionableADMAADMA Biologics530238.16 million228.87 millionOptionableALLOAllogene Therapeutics310244.82 million212.50 millionOptionablePCVXVaxcyte160144.40 million139.92 millionOptionableADMA, ACAD, ALLO, and PCVX HeadlinesRecent News About These CompaniesVaxcyte Target of Unusually Large Options Trading (NASDAQ:PCVX)May 13 at 3:47 AM | americanbankingnews.comVaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12 at 8:05 PM | seekingalpha.comVaxcyte, Inc. $PCVX Shares Sold by State of New Jersey Common Pension Fund DMay 11 at 5:00 AM | marketbeat.comNan Fung Trinity HK Ltd. Acquires 38,680 Shares of Vaxcyte, Inc. $PCVXMay 10, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Misses Estimates By $0.56 EPSMay 6, 2026 | marketbeat.comVaxcyte Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comVaxcyte, Inc. $PCVX Shares Purchased by UBS Group AGMay 6, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Price Down 6.8% - What's Next?May 5, 2026 | marketbeat.comVanguard Group Inc. Sells 126,467 Shares of Vaxcyte, Inc. $PCVXMay 5, 2026 | marketbeat.comJennison Associates LLC Has $31.26 Million Stock Position in Vaxcyte, Inc. $PCVXMay 2, 2026 | marketbeat.comVaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV MarketMay 1, 2026 | seekingalpha.comVaxcyte (NASDAQ:PCVX) COO Sells $127,867.50 in StockMay 1, 2026 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Raises Stake in Vaxcyte, Inc. $PCVXMay 1, 2026 | marketbeat.comPictet Asset Management Holding SA Has $40.67 Million Stock Position in Vaxcyte, Inc. $PCVXApril 30, 2026 | marketbeat.comVaxcyte (PCVX) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comVaxcyte (NASDAQ:PCVX) Rating Lowered to Strong Sell at Wall Street ZenApril 28, 2026 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 26, 2026 | marketbeat.com5 Best 52-Week High US Stocks to BuyApril 23, 2026 | insidermonkey.comVaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial StageApril 23, 2026 | insidermonkey.comVaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street ZenApril 20, 2026 | marketbeat.comIs It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump?April 11, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Alcoa Rebounds as Aluminum Tightens, But a Q1 Miss Tests the RallyBy Jessica Mitacek | April 22, 2026Broadcom Hits $2 Trillion Market Cap as Google Reveals New AI ChipsBy Leo Miller | April 28, 20263 Small-Cap Stocks to Buy as the Russell 2000 Extends Its RallyBy Chris Markoch | May 11, 2026The PDT Rule Is On Its Way Out: 5 Stocks That Stand to Benefit the MostBy Ryan Hasson | April 20, 2026ADMA, ACAD, ALLO, and PCVX Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$22.13 -0.05 (-0.23%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.ADMA Biologics NASDAQ:ADMA$8.49 -0.01 (-0.07%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Allogene Therapeutics NASDAQ:ALLO$2.22 -0.11 (-4.51%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Vaxcyte NASDAQ:PCVX$53.68 -0.58 (-1.06%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI A New Focus for GoPro: Is a Takeover in the Frame? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
